At 81 months of followup, the STAR P-2 trial between Tamoxifen and Raloxifene shows both are effective in preventing breast cancer recurrence, but the Raloxifene has fewer side effects for many women.
Taloxifene improves its effectiveness against noninvasive b/c and caused significantly less endometrial cancer, and was significantly less toxic than Tamoxifen.
I am not a physician, not very knowledgeable about breast cancer, but if you are involved with this subject, this is worth checking out, in my opinion.
Here is a teleconference you can download: http://aacrnews.wordpress.com/2010/04/19/teleconference-study-of-tamoxifen-and-raloxifene-star-p-2/
Again—talk to your doctor.
0 comments:
Post a Comment